The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
SAN DIEGO, Oct. 26, 2023 Oncternal Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and.
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.